Category: 226942-29-6

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,226942-29-6

5-Cyclopropyl-2,6-dimethyl-7-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)oxazolo[4,5-c]- quinolin-4-one (Intermediate B) (69 mg, 0.18 mmol), [1 , T- bis(diphenylphosphino)ferrocene]palladium(ll) chloride dichloromethane complex (14 mg, 0.02 mmol), CS2CO3 (178 mg, 0.55 mmol), and 6-bromo-1 ,2,3,4-tetrahydroisoquinoline (38 mg, 0.18 mmol) were dissolved in a mixture of monoglyme (1 mL) and H2O (0.3 mL). The reaction solution was then irradiated with microwaves at 60C for 30 min. The solution was diluted with MeOH, filtered, dry-loaded onto silica and purified by flash chromatography using a gradient of 0-10% MeOH in DCM. The fractions containing the required product were then concentrated in vacuo to give 5-cyclopropyl-2,6-dimethyl-7-(1 , 2,3,4- tetrahydroisoquinolin-6-yl)oxazolo[4,5-c]-quinolin-4-one (2 mg, 3 %) as a pale yellow solid. 1 H NMR (Method A) (CDC ): delta 7.70 (d, J = 8.0 Hz, 1 H), 7.23 (d, J = 8.0 Hz, 1 H), 7.19 – 7.10 (m, 3H), 4.15 (s, 2H), 3.62 (m, 1 H), 3.25 (t, 2H), 2.93 (t, 2H), 2.68 (s, 3H), 2.53 (s, 3H), 1.31 – 1.26 (m, 2H), 0.71 – 0.65 (m, 2H); LC-MS (Method D) 386.4 [M+H]+; RT 1.68 min

226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; REDX PHARMA PLC; HUXLEY, Anthony; KIRK, Ralph; RATCLIFFE, Andrew; LYTH, David; (112 pag.)WO2017/46605; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Name is 6-Bromo-1,2,3,4-tetrahydroisoquinoline, as a common heterocyclic compound, it belongs to tetrahydroisoquinoline compound, and cas is 226942-29-6, its synthesis route is as follows.,226942-29-6

5-Cyclopropyl-2,6-dimethyl-7-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)oxazolo[4,5-c]- quinolin-4-one (Intermediate B) (69 mg, 0.18 mmol), [1 , T- bis(diphenylphosphino)ferrocene]palladium(ll) chloride dichloromethane complex (14 mg, 0.02 mmol), CS2CO3 (178 mg, 0.55 mmol), and 6-bromo-1 ,2,3,4-tetrahydroisoquinoline (38 mg, 0.18 mmol) were dissolved in a mixture of monoglyme (1 mL) and H2O (0.3 mL). The reaction solution was then irradiated with microwaves at 60C for 30 min. The solution was diluted with MeOH, filtered, dry-loaded onto silica and purified by flash chromatography using a gradient of 0-10% MeOH in DCM. The fractions containing the required product were then concentrated in vacuo to give 5-cyclopropyl-2,6-dimethyl-7-(1 , 2,3,4- tetrahydroisoquinolin-6-yl)oxazolo[4,5-c]-quinolin-4-one (2 mg, 3 %) as a pale yellow solid. 1 H NMR (Method A) (CDC ): delta 7.70 (d, J = 8.0 Hz, 1 H), 7.23 (d, J = 8.0 Hz, 1 H), 7.19 – 7.10 (m, 3H), 4.15 (s, 2H), 3.62 (m, 1 H), 3.25 (t, 2H), 2.93 (t, 2H), 2.68 (s, 3H), 2.53 (s, 3H), 1.31 – 1.26 (m, 2H), 0.71 – 0.65 (m, 2H); LC-MS (Method D) 386.4 [M+H]+; RT 1.68 min

With the complex challenges of chemical substances, we look forward to future research findings about 6-Bromo-1,2,3,4-tetrahydroisoquinoline

Reference£º
Patent; REDX PHARMA PLC; HUXLEY, Anthony; KIRK, Ralph; RATCLIFFE, Andrew; LYTH, David; (112 pag.)WO2017/46605; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

As a common heterocyclic compound, it belongs to tetrahydroisoquinoline compound, name is 6-Bromo-1,2,3,4-tetrahydroisoquinoline, and cas is 226942-29-6, its synthesis route is as follows.,226942-29-6

Boc2O (3.52 g, 16.14 mmol) was added to a solution of 6-bromo-1,2,3,4-tetrahydroisoquinoline (3.26 g, 15.37 mmol) in THF (45 mL) at room temperature, and the mixture was stirred at room temperature for 15 hr. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent gradient; 0?8% ethyl acetate/hexane) to give tert-butyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (5.05 g, 16.18 mmol, quant.) as a colorless oil. 1H NMR (300 MHz, CDCl3):delta 1.49(9H,s), 2.80(2H,t,J=5.9 Hz), 3.62(2H,t,J=5.9 Hz), 4.51(2H,s), 6.97(1H,d,J=8.7 Hz), 7.28-7.32(2H,m).

With the complex challenges of chemical substances, we look forward to future research findings about 226942-29-6,belong tetrahydroisoquinoline compound

Reference£º
Patent; Takeda Pharmaceutical Company Limited; YAMAMOTO, Satoshi; SHIRAI, Junya; ODA, Tsuneo; IMADA, Takashi; KONO, Mitsunori; SATO, Ayumu; TOMATA, Yoshihide; OCHIDA, Atsuko; ISHII, Naoki; SASAKI, Yusuke; FUKASE, Yoshiyuki; YUKAWA, Tomoya; FUKUMOTO, Shoji; (200 pag.)EP3192791; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Name is 6-Bromo-1,2,3,4-tetrahydroisoquinoline, as a common heterocyclic compound, it belongs to tetrahydroisoquinoline compound, and cas is 226942-29-6, its synthesis route is as follows.,226942-29-6

To a solution of 6-bromo-1,2,3,4-tetrahydroisoquinoline (1.25 g, 5.88 mmol) in DCM (25 mL) was added 2-chloro-6-methylbenzaldehyde (1.0 g, 6.5 mmol) and acetic acid (0.337 mL, 5.88 mmol) inDCM (25 mL). Then sodium triacetoxyborohydride (1.62 g, 7.64 mmol) was added. Themixture was stirred at r.t for 16 hrs. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by recrystallization with EtOAc to give 6-bromo- 2-(2-chloro-6-methylbenzyl)-1,2,3,4-tetrahydroisoquinoline (1.44 g, 4.11 mmol, 69.8%yield). LCMS (M+H): 350.00, 352.00.

With the complex challenges of chemical substances, we look forward to future research findings about 6-Bromo-1,2,3,4-tetrahydroisoquinoline

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; EASTMAN, Kyle J.; KADOW, John F.; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PATEL, Manoj; SIVAPRAKASAM, Prasanna; TU, Yong; (275 pag.)WO2017/25915; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

A common heterocyclic compound, the tetrahydroisoquinoline compound, name is 6-Bromo-1,2,3,4-tetrahydroisoquinoline,cas is 226942-29-6, mainly used in chemical industry, its synthesis route is as follows.

A mixture of 6-bromo-l,2,3,4-tetrahydroisoquinoline (2 g, 9.43 mmol), Boc20 (2.26 g, 2.41 mL, 10.4 mmol) and Et3N (1.91 g, 2.63 mL, 18.9 mmol) in THF (30 mL) was stirred at rt. For 3 hrs. The resulting mixture was diluted with aqueous Na2C03 solution and extracted with EA (30 mL) twice. The combined organic layer was washed with brine, dried over aqueous Na2S04, filtered, and concentrated in vacuo to afford tert-butyl 6-bromo-3,4-dihydro-lH- isoquinoline-2-carboxylate (2.9 g) as white solid which was directly used in the next step without any further purification

226942-29-6, As the rapid development of chemical substances, we look forward to future research findings about 226942-29-6

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; CHENG, Zhanling; WANG, Jianhua; WANG, Min; YANG, Song; (81 pag.)WO2018/83136; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,226942-29-6

To a solution of 6- bromo-l,2,3,4-tetrahydroisoquinoline (4.19 g, 19.7 mmol) in DCM (75 mL) was added 4- fluoro-2-methylbenzaldehyde (3.0 g, 22 mmol) and acetic acid (1.13 mL, 19.7 mmol). Then sodium triacetoxyborohydride (5.4 g, 26 mmol) was added. The mixture was stirred at RT for 16 hrs. The mixture was quenched with water and extracted with DCM. The organic layer was washed with brine, dried over Na2S04 and concentrated. The residue was purified by recrystallization with EtOAc to give 6-bromo-2-(4-fluoro-2- methylbenzyl)-l,2,3,4-tetrahydroisoquinoline (3.4 g, 10.17 mmol, 51.5 % yield). LCMS (M+H) = 333.95 and 335.90.

226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.

To a mixture of 4-(2-chloro-4-pyrimidinyl)mophiholine (910 mg, 4.56 mmol) and 6-bromo-l,2,3,4- tetrahydroisoquinoline (967 mg, 4.56 mmol) is added anhydrous NMP (12 mL) and the reaction is flushed well with nitrogen. The reaction is then treated with NN- diisopropylethylamine (2.0 mL, 11.45 mmol), capped and placed in a 120 C oil bath for 16 hours. Crude LC/MS seems to indicate complete conversion to the desired product. Removed NuMuRho and Hunig’s base under a stream of nitrogen while heating at 80 C overnight. A yellow solid remained. Took up the solid in EtOAc, heated to dissolve most material in minimum amount of solvent, filtered while hot, allow to cool to RT slowly to give 1.65g (91%) of 4-(2-(6-bromo-3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-4- yl)morpholine as a pale yellow solid as recrystallized material. LCMS (M+l) = 374.7 and (0235) 376.7., 226942-29-6

The synthetic route of 226942-29-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.

To a solution of 6-broino- I ,2,3,4-tetrahydro- iso-quinoline (1500 g, 71.1 mrnol) in DCM (160 mL) was added activated Mn0 (77.84 g, 859.7mmol). The mixture was stirred for 18 h at 11 and filtered. The filtrate was concentrated n vacuo, and the residue was purified by silica gel chroniatographv (PE:EtOAc =20:1 to 5:1) to afford the title compound.

226942-29-6, The synthetic route of 226942-29-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; ADAMS, Gregory, L.; COX, Jason, M.; DEBENHAM, John, S.; EDMONDSON, Scott; GILBERT, Eric, J.; GUO, Yan; JIANG, Yu; JOSIEN, Hubert; KIM, Hyunjin, M.; LAN, Ping; MIAO, Shouwu; PLUMMER, Christopher, W.; RAJAGOPALAN, Murali; SHAH, Unmesh; SUN, Zhongxiang; TRUONG, Quang, T.; UJJAINWALLA, Feroze; VELAZQUEZ, Francisco; VENKATRAMAN, Srikanth; SUZUKI, Takao; WANG, Nengxue; (182 pag.)WO2017/205193; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem